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Abstract: We report the 5-year follow-up of a young woman who developed vertebral fractures 
after pregnancy and lactation and was treated with active vitamin D hormone. A 32-year-old 
Japanese woman consulted us because of acute lower back pain caused by L2 and L5 vertebral 
fractures after pregnancy and lactation. Following cessation of breast-feeding, analgesia, bed rest, 
and wearing of a hard brace, her lower back pain disappeared within 2 months. After 5 years of 
treatment with alfacalcidol 1 µg daily, the lumbar spine (L1, L3, L4) bone mineral density 
increased by 21.4% following vigorous reductions in bone turnover markers. No osteoporotic 
fractures occurred, and the vertebral fractures healed. The patient experienced no side effects, 
including hypercalcemia. Thus, the present case report shows long-term changes in bone 
turnover markers and lumbar spine bone mineral density, as well as long-term safety of alfa-
calcidol treatment in a young woman with pregnancy and lactation-associated osteoporosis 
and vertebral fractures.
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Background
Pregnancy and lactation-associated osteoporosis are rare conditions characterized by 
significant changes in calcium and bone homeostasis arising from the increased fetal 
demand for calcium for skeletal bone calcification and the subsequent occurrence of 
fragility fractures during late pregnancy or during the postpartum period.1,2 To date, no 
good evidence to guide medicinal interventions is available in patients with pregnancy 
and lactation-associated osteoporosis.
Given that calcium imbalances during pregnancy and the lactation period are not 
surprising,1,2 therapeutic options primarily include calcium and vitamin D supplemen-
tation in an appropriate clinical setting.3 In Japan, nutritional calcium and vitamin D 
supplements are not widely available, and active vitamin D hormones are alternatively 
used. We report the 5-year follow-up of a young woman with acute lower back pain 
caused by lumbar vertebral fractures after pregnancy and lactation who was treated 
with active vitamin D hormone.
Case report
A young 32-year-old Japanese woman consulted our clinic because of nontraumatic 
acute lower back pain. Her height was 155 cm, her body weight was 57 kg, and her 
body mass index was 23.7 kg/m2. She had given birth to a baby 3 months before her 
visit to our clinic and had breastfed the baby for 3 months. She had no past history 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
195
CASE REPORT
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/TCRM.S30668Therapeutics and Clinical Risk Management 2012:8
of metabolic bone disease and had never taken medicine 
affecting bone metabolism. She did not have any clinical risk 
factors for fractures, including current smoking, a maternal 
history of hip fractures, alcohol consumption $2 units daily, 
age $75 years, leanness (body mass index #18.5 kg/m2), or 
a history of steroid use.4
Although radiographs of the lumbar spine did not show 
any obvious vertebral (morphometric) fractures in the lum-
bar spine,5,6 magnetic resonance imaging detected clinical 
vertebral fractures at the L2 and L5 spine (Figure 1). She 
was hospitalized for treatment. She stopped lactation and 
was restricted to bed rest with the occasional use of non-
steroidal anti-inflammatory drugs. After 2 weeks of bed 
rest, her lower back pain had significantly improved, the 
occasional use of non-steroidal anti-inflammatory drugs 
was stopped, and rehabilitation was started, with the patient 
wearing a hard brace.
The lumbar spine bone mineral density (BMD) in the 
anteroposterior view was measured using dual-energy x-ray 
absorptiometry, and biochemical analyses were performed. 
Table 1 shows the baseline bone mineral density and bio-
chemical markers. The patient was diagnosed as having high 
bone turnover osteoporosis.5,6 Treatment with alfacalcidol 
1 µg daily was started, and the patient was discharged from 
hospital.
Outcome of 5 years of treatment  
with alfacalcidol
The patient’s lower back pain was alleviated after 2 months of 
treatment, bony union was confirmed, and the hard brace was 
removed. The lumbar spine BMD increased from the baseline 
value (Figure 2) and reached 0.906 g/cm2,   corresponding 
to 92% of the age-matched control. Figures 3 and 4 show 
changes in biochemical markers. Serum alkaline phos-
phatase, bone alkaline phosphatase, parathyroid levels, and 
urinary N-terminal telopeptide levels were within the normal 
range after 5 years of alfacalcidol treatment.
At 5 years, radiographs of the thoracic and lumbar spine 
revealed no evidence of new thoracic or lumbar morpho-
metric vertebral fractures,5,6 and the L2 and L5 vertebral 
fractures had healed with small height loss of the vertebral 
bodies (  Figure 5). During the 5-year period of alfacalcidol 
treatment, non-vertebral osteoporotic fractures did not occur. 
Furthermore, neither hypercalcemia nor adverse effects 
were observed. The treatment was discontinued when the 
patient became pregnant again after 5 years of treatment 
with alfacalcidol.
Table 1 BMD and biochemical markers before treatment
Normal range
Lumbar spine BMD (g/cm2) 0.746
% YAM in BMD 74
% AMC in BMD 75
Serum
  Calcium (mg/dL) 8.9 8.4–10.2
  Phosphorus (mg/dL) 4.1 2.5–4.5
  ALP (IU/L) 398 100–340
  Intact PTH (pg/mL) 10.3 10–66
  BAP (µg/L) 49.7 3.8–22.6
Urine
  NTX (nM BCE/mM Cr) 85.3 9.3–54.3
  Calcium/Cr 0.098 ,0.3
Abbreviations: BMD, bone mineral density; YAM, young adult mean; AMC, age-
matched control; ALP, alkaline phosphatase; PTH, parathyroid hormone; BAP, bone-
specific alkaline phosphatase; NTX, cross linked N-terminal telopeptides of type I 
collagen; BCE, bone collagen equivalent; Cr, creatinine.
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Figure 1 Radiographs and MR images of the lumbar spine – lateral views before treatment.
Notes: Radiographs of the lumbar spine did not show any obvious vertebral fractures (morphometric fractures) in the lumbar spine. However, T1-weighted MR images 
identified low-intensity areas and T2-weighted and STIR MR images identified high-intensity areas at the L2 and L5 vertebral bodies.
Abbreviations: MR, magnetic resonance; STIR, short-tau inversion-recovery.
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Discussion
Pregnancy and lactation place a large amount of stress on 
maternal calcium homeostasis. Physiologically, there are 
increased calcium requirements during pregnancy, particu-
larly during the third trimester when rapid mineralization of 
the fetal skeleton occurs.7 This increase is compensated for 
by increased intestinal absorption, reduced urinary calcium 
excretion, and increased bone resorption.8 The degree of the 
reduction in BMD during pregnancy, in the range of 2%–4%, 
depending on the site of measurement.9 During lactation, the 
reduction in BMD approximates the duration of lactation, 
with significant reductions in both the hip and lumbar spine.7 
Approximately 5% of the BMD is lost in the lumbar spine 
and femoral neck during lactation lasting for 6 months or 
longer.10 In the current patient with low BMD, bone turnover 
increased, but release of excess calcium from this resorptive 
process in terms of hypercalcemia and hypercalciuria was not 
observed. Parathyroid gland function was mildly suppressed, 
probably because of physiological changes in intestinal cal-
cium absorption and renal calcium reabsorption.
Patients with pregnancy and lactation-associated 
osteoporosis can expect to return to normal 6–12 months 
after breast-feeding has stopped.7 Although the bone 
turnover markers were normalized, the lumbar spine BMD 
remained low. This finding suggests a pre-existing low 
lumbar spine BMD.
A couple of studies have shown that the effects of one year 
of treatment with alfacalcidol on the lumbar spine BMD and 
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Figure 2 Changes in lumbar spine BMD. 
Notes: The lumbar spine BMD increased from the baseline value. The increase in 
the lumbar spine BMD after 5 years of treatment with alfacalcidol was 21.4%.
Abbreviation: BMD, bone mineral density.
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Figure 3 Changes in serum calcium, phosphorus, ALP, and intact PTH. 
Notes: The serum ALP levels tended to decrease, and the serum intact PTH levels tended to increase from the baseline values. The serum levels of calcium and phosphorus 
stayed within the normal ranges. The decrease in the serum ALP levels after 5 years of treatment with alfacalcidol was 59.8%. The increase in the serum intact PTH level 
was 220%.
Abbreviations: ALP, alkaline phosphatase; PTH, parathyroid hormone.
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bone turnover markers were modest among Japanese patients 
with involutional and postmenopausal osteoporosis.11,12 Thus, 
the dramatic changes in bone turnover markers and intact 
parathyroid hormone in the current patient could be mostly 
attributed to the natural course of pregnancy and lactation-
associated osteoporosis, combined with the cessation of 
breast-feeding. However, there may have been small effects of 
alfacalcidol on bone turnover markers and lumbar spine BMD. 
No osteoporotic fractures occurred, and neither hypercalcemia 
nor adverse effects were observed. Thus, the present case 
report showed long-term changes in bone turnover markers 
and lumbar spine BMD, as well as the long-term safety of 
alfacalcidol treatment in a young woman with pregnancy and 
lactation-associated osteoporosis and vertebral fractures.
(months)
(µg/L) (nM BCE/mM Cr)
0
10
20
30
40
50
60
0 1 41 0 18 32 48 60 (months) 0 1 41 0 18 32 48 60
0
20
40
60
80
100
120
BAP Urinary NTX
Figure 4 Changes in bone turnover markers. 
Notes: The serum BAP levels and urinary NTX levels tended to decrease from the baseline values. The decrease in the serum BAP levels and the urinary NTX levels after 
5 years of treatment with alfacalcidol were 75.7% and 58.3%, respectively.
Abbreviations: BAP, bone-specific alkaline phosphatase; NTX, cross-linked N-terminal telopeptides of type I collagen.
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Figure 5 Radiographs of the thoracic and lumbar spine – lateral views after 5 years of treatment.
Notes: After 5 years of alfacalcidol treatment, radiographs of the thoracic and lumbar spine revealed no evidence of new thoracic or lumbar vertebral fractures, and the L2 
and L5 vertebral fractures had healed.
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In conclusion, the present case report shows long-term 
changes in bone turnover markers and lumbar spine BMD, 
as well as long-term safety of alfacalcidol treatment, in 
a young woman with pregnancy and lactation-associated 
osteoporosis and vertebral fractures.
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